Comparative study of amlodipine versus ramipril and their effects on markers of renal disease in type 2 diabetes mellitus
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20160762Keywords:
T2DM, Predicators/Markers of renal disease, ACEI (Angiotensin Converting Enzyme Inhibitor), Blood Pressure, Calcium channel blocker (CCBs), Renoprotective, eGFR, MicroalbuminuriaAbstract
Background: Diabetes mellitus is a chronic metabolic condition and patients require long treatment for it. The aim of the study was to evaluate the effects of amlodipine and ramipril on the blood pressure and markers of renal disease (viz. serum creatinine, albuminuria and eGFR) in type 2 diabetes mellitus.
Methods: This was a randomized, open labelled, parallel study conducted to assess the effect of Amlodipine (2.5-10 mg) and Ramipril (2.5-10 mg) daily for 24 weeks in T2DM patients (n=103). Patients were recruited from department of Medicine OPD/Ward in the GGS Hospital and Medical College, Faridkot. Subjects in the age group of 30- 80 years who had T2DM with or without hypertension were enrolled and randomly divided into two groups viz. Group A (n=51, amlodipine 2.5 to 10 mg/day) and Group B (n=52, ramipril 2.5 to 10mg/day). Patients were evaluated at day 0 and then at 12 and 24 weeks for Blood pressure, S. Creatinine, albuminuria, eGFR and other routine investigations.
Results: At 24 weeks SBP, DBP and MAP values were decreased significantly in both the groups (p <0.0001, each). At 24 weeks, there were increased in the levels of albumin in urine (59.87%, p<0.0001) and serum creatinine (24.93%, p< 0.001) in the Amlodipine group while fall in these levels were observed (26.75%, p<0.0001 and 5.95%, p>0.05) in Ramipril group. eGFR was decreased (9.73%, p <0.01) in Amlodipine group while increased in Ramipril group (10.29%, p<0.01 %).
Conclusions: Both amlodipine and ramipril are equally efficacious in improving SBP, DBP and MAP in T2DM patients. Whereas, ramipril is also improves the markers/predictors of renal disease (viz. serum creatinine, albumin level in urine and eGFR) in T2DM patients, furthermore, it is having renoprotective action in an addition to lowering raised blood pressure which is useful to treat diabetic nephropathy cases.
References
Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL. Powers AC. Diabetes Mellitus. In. Harrison’s Princples of Internal Medicine. 17th edition. New York: McGraw-Hill Medical Publishing division. 2008:2275-2304.
World Health Organization. Development and Updation of the diabetes Mellitus ATLAS of India. Available at: http:www.whoindia.org/Link Files/ NMH_Resources_Diabetes_atlas.pdf. Accessed on 1 April 2011.
Wild S, Roglic G, Green A, Sicree R, King J. Global prevalence of diabetes-Estimates for the year 2000 and projections for 2030, Diabetes Care. 2004;27:1047-53.
International Diabetes Federation. IDF Diabetes Atlas Sixth edition. Available at https://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Assessed on 17 Oct. 2015.
Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ. 2013;347:f5680. Available at: http://www.bmj.com/content/bmj/347/bmj.f5680.ful.pdf. Accessed on 17 Oct 2015 at 06:38 AM.
International Diabetes Federation. Metabolic syndrome-driving the CVD epidemic. Available at https://www.idf.org/webdata/docs/Diabetes_meta_syndrome.pdf. Accessed on 17 Oct 2015 at 08:10 AM.
Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Cass A. Prevention and management of chronic kidney disease in type 2 diabetes. Nephrology. 2010;15:S162-94.
Benowitz NL. Antihypertensive Agents. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th edition. New Delhi: Tata McGraw-Hill Education Private Limited. 2009:167-189.
Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG. Clinical Practice Guidelines for the Management of Hypertension in the Community A Statement by the American Society of Hypertension and the International Society of Hypertension. The Journal of Clinical Hypertension. 2014;16(1):14-26. Available at http://csc.cma.org.cn/attachment/2014315/1394885445745.pdf. Assessed on 17 Oct 2015.
Kumar R, Kohli K, Kajal HL. A study of drug prescribing pattern and cost analysis among diabetic patients in a tertiary care teaching institute in north India. Journal of Drug Delivery & Therapeutics; 2013;3(2):56-61. Available at http://jddtonline.info/index.php/jddt/article/view/431/246. Assessed on 17 Oct 2015.
Gitanjali, Goyal S, Panag KMDS. Role of urinary albumin to creatinine ratio and spot albuminuria in predicting significant albuminuria in patients of diabetic nephropathy. Journal of Evolution of Medical and Dental Sciences; 2014;3(1):38-45.
Pahor M, Franse LV, Deitcher SR, Cushman WC, Johnson KC, Shorr RI. Fosinopril Versus Amlodipine Comparative Treatments Study- A Randomized Trial to Assess Effects on Plasminogen Activator Inhibitor-1. Circulation. 2002;105:457-61.
Zaman ZA, Kumari V. Comparison of the effects of amlodipine and cilnidipine on blood pressure, heart rate, proteinuria and lipid profile in hypertensive patients. Int J Basic Clin Pharmacol. 2013;2:160-4.
Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA. 2001;285(21):2719-28.
Kojima S, Shida M, Yokoyama H. Comparison between Cilnidipine and Amlodipine Besilate with Respect to Proteinuria in Hypertensive Patients with Renal Diseases. Hypertens Res. 2004;27(6):379-85.
Soni U, Moghe VV, Jain P, Upadhyaya P. A Comparative Study of Efficacy and Tolerability of Telmisertan and Ramipril. International Journal of Pharma Sciences. 2013;3(3):240-43.
Andersen K, Weinberger MH, Egan B, Constance CM, Wright M, Lukashevich. Comparative Efficacy of Aliskiren Monotherapy and Ramipril Monotherapy in Patients with stage 2 Systolic Hypertension: Subgroup Analysis of a Double-blind, Active Comparator Trial. Cardiovascular Therapeutics. 2010;28:344-49.
Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-Receptor Blockade versus Converting-enzyme Inhibition in Type 2 Diabetes and Nephropathy. N Engl J Med. 2004;4:351(19):1952-61.
